Health Canada
Symbol of the Government of Canada

Common menu bar links

About Health Canada

Access to Information Requests Completed - July 2015

The following is a list of Access to Information requests processed by Health Canada. The list is not all-inclusive. The list contains requests completed for which documents have been retrieved or treated. The list is provided in chronological order, by month and year, and by request number. (Requests focusing on personal information or third party proprietary information are not included.)

If you wish to obtain a copy of the records released in response to these requests informally, you may contact the Access to Information and Privacy Division.

For the month of July 2015
Request # Summary of Requests Status of Completed Request Number of Pages Disclosed
A-2012-00931 Information on how Health Canada, Aboriginal Affairs and Northern Development Canada, Indian Residential Schools Resolution Canada, and the Indian Residential Schools Adjudication Secretariat share information/data collected from the Independent Assessment Process (IAP) application form and what types of IAP information is shared with Health Canada. (Jan. 1, 2006 to Sep. 19, 2012) All disclosed 13
A-2013-00326 All documents and correspondence between Health Canada and Pharmascience (PMS) in relation to submission status or non-compliance of submission for PMS Zopiclone Disclosed in part 53
A-2013-01127 Documentation related to communication with the Health Minister's office (MO), either Rona Ambrose or her predecessor Leona Aglukkaq, Deputy Minister (DM) George Da Pont and MO/DM staffs, which deal with the abortion drug Mifepristone (also known as RU-486). (Dec. 20 2013 to Dec. 20 2014) Disclosed in part 44
A-2013-01151 Efficacy and safety studies on STIEVAMYCIN FORTE. Drug Identification Number: 01945262 Disclosed in part 41
A-2014-00743 All materials and investigation reports regarding harassment, including full copies of all investigation files created to settle any complaints and held by the Department of Health and its directorates and branches: Human Resources, Labour Relations and Wellness (Office for Respect in the Workplace); the First Nations and Inuit Health Branch, Quebec Region; Public Health Agency of Canada, Quebec Region (Jan. 1, 2008 to Sep. 26, 2014) Disclosed in part 290
A-2014-00966 Adverse Reaction Report (AER) for Plaquenil (hydrochloroquine sulfate). Report number: 000567540 Disclosed in part 4
A-2014-01028 Copy of the Class III Medical Device License Application Form: DIAM-SPINAL STABILIZATION SYSTEM License Number 69163, with information related to the purpose/intended use of Device, the device history, the compatibility of interdependent devices and the review documents. Disclosed in part 90
A-2014-01123 All documents in Ministerial Executive Correspondence System (MECS) for the following file: 14-106646-151. Subject: Follow-up discussion on funding - sex trade workers (May26, 2014) No records exist 0
A-2014-01171 Documents related to 2013 and 2014 contract deliverables for Arizone One #4500321910 All disclosed 145
A-2014-01212 All documents regarding the review and processing of the Marihuana for Medical Purposes Regulations license application number 10-MM0021. All exempted 0
A-2014-01306 Adverse Reaction Report (AER) for Humira. Report numbers: 000625078, 000626835 and 00627564 Disclosed in part 10
A-2014-01328 Communications (e-mails) of Dr. McNamee regarding the following events related to Safety Code 6:
  • July 9, 2014 - Media conference
  • September 12, 2014 - Symposium
  • January 19, 2015 - Media conference on Bill C-648
All disclosed 2
A-2014-01389 Information on applications under the Special Access Program regarding drugs made for pharmaceutical: mifepristone or RU-486. (Jan. 1, 2014 to Feb. 17, 2015) Disclosed in part 15
A-2014-01418 Adverse Reaction Report (AER) for Cipralex«. Report numbers: 000614888, 000623879, 000624163, 000630414, 00620764, 000625760, 000624781, 000625998, 000620979, 000626276, 000624329, 000624028, 000619911 and 000624751. Disclosed in part 62
A-2014-01438 All documents regarding decision making process to deny applicants a license under the Marihuana for Medical Purposes Regulations, as well as all correspondence from the Minister's office. (Jan. 1, 2014 to Mar.4, 2015) Disclosed in part 4
A-2014-01474 Copy of the "Priority Evaluation Request" document sent to your institution and accepted on July 13, 2001, from the manufacturer requesting to apply to license DUKORAL in Canada Disclosed in part 11
A-2014-01504 Copy of Health Canada Marihuana for Medical Purposes Regulations (MMPR) documents CS-GD-010 MMPR Compliance Management and Endpoints Disclosed in part 17
A-2014-01506 Copy of Health Canada documents CS-OF-OO1 Operational Framework for Compliance and Enforcement Activities for the Marihuana for Medical Purposes Regulations (MMPR) Disclosed in part 8
A-2014-01557 All documents in MECS for the following file: 14-114220-417. Subject: Nutrition North Canada All excluded 0
A-2014-01569 Documents related to the feasibility assessment and business case pertaining to developing a Canadian surveillance system for poisonings, chemical intoxications and adverse drug reactions, as per Merx Solicitation No. 1000163953. Disclosed in part 112
A-2015-00005 Adverse Reaction Report (AER) for Thymoglobulin (anti-thymocyte globulin). Report number: E2B-00125370. Disclosed in part 17
A-2015-00014 All adverse drug reaction reports for the Nephrogenic Systemic Fibrosis (NSF) symptoms associated with the use of MULTIHANCE« glalinium-based contract agents (GBCAs).
Time frame: from the NDS application for MULTIHANCE« to April 10, 2015.
No records exist 0
A-2015-00023 Adverse Reaction Report (AER) for the following products/report numbers: "Actos" (000634785), "Alvesco" (000633506, 000634881, 000635751, 000641862), "Feraheme" (000631221, 000631431, 000631847, 000634527, 000635557, 00630756), "Dexilant" (000634782, 000633170, 000629825, 000628580) Disclosed in part 25
A-2015-00041 All documents relating to and the spirit of achieving Treasury Board Secretariat Contracting Policy 4.1.9b, ensuring that employer-employee relationships will not result when individuals are awarded Service Contracts by Health Canada (Jan. 1, 2011 to Apr. 15, 2015) All disclosed 1,098
A-2015-00043 Documentation relating to the final investigative reports of all harassment investigations conducted by the government supplier / contractor Ancien Group Inc. (Apr. 15, 2009 to Apr. 15, 2015) Disclosed in part 10
A-2015-00054 Documentation relating to 2013 and 2014 contract deliverables for Summit Toxiology #4500306874 All disclosed 48
A-2015-00058 List of all legal tobacco products currently sold in Canada as of April 20, 2015. All disclosed 115
A-2015-00086 Adverse Reaction Report (AER) for KALETRA. Report numbers: 000634758, 000634763 and 000634764. Disclosed in part 20
A-2015-00092 Adverse Reaction Report (AER) for ISOFLURANE. Report numbers: 000631655, 000631702 and 000633034. Disclosed in part 11
A-2015-00119 All documents in MECS for the following file: 14-113262-875. Subject: Briefing Note: October 27, 2014 / Traditional Chinese Medicine Meeting Disclosed in part 100
A-2015-00122 Document pertaining to the Counterfeit Drugs and Online Orders of Pharmaceuticals in Canada study or research (Jan. 2012) All disclosed 12
A-2015-00133 Adverse Reaction Report (AER). Report number: E2B_00203105. All disclosed 8
A-2015-00139 All documents pertaining to candidates involved in staffing process 14-AHS-HSI-IA-NCR-108797, as well as communications among the managers responsible for hiring and the Human Resources Directorate and information related to the staffing process. Disclosed in part 1,626
A-2015-00144 Document indicating the total amount per year paid to Protak Consulting Group, Inc., and/or A. Elsaadi & Associates, Inc. (Jan. 1, 2009 and May 19, 2015) All disclosed 3
A-2015-00145 Adverse Reaction Report (AER) for Arava (leuflunomide). Report number: E2B_00013679. Disclosed in part 14
A-2015-00154 Adverse Reaction Report (AER) for Pediacel vaccine. Report number: 000628628. Disclosed in part 3
A-2015-00160 Information related to the number of applications received under the Controlled Drugs and Substances Act (the Act) since 1996 interested in producing and extracting Cannabidiol (CBD) from hemp and/or marihuana and the number of dealers approved by Health Canada under the Act, OR, information on the number of applications received and the number of dealers approved by Health Canada since December 2012, following the Marihuana for Medical Purposes Regulations announcement. All disclosed 1
A-2015-00172 List of contracts awarded to each of the firms/companies appointed below for investigation, audit, evaluation, analysis, studies, research and other mandates for the years 2005 to 2015 (May 27, 2015):
  • Raymond Chabot Grant Thornton (RCGT)
  • Samson BÚlair/ Deloitte & Touche (Deloitte)
  • PricewaterhouseCoopers (PwC)
  • Ernst & Young (E&Y)
  • PMG, KPMG Forensic Inc. * KPMG LLP Mallette
  • RSM Richter Chamberland
  • BDO Canada
  • Groupe RDL
  • Fauteux Bruno Bussieres Leewarden (FBBL)
  • Spearhead Management Canada LtÚe
  • Deloitte LLP
All disclosed 23
A-2015-00184 Document indicating the number of sick days taken by Health Canada's employees in the National Capital Region in each of the last three completed fiscal years. All disclosed 1
A-2015-00185 Copy of the Marihuana for Medical Purposes Regulations (MMPR) reporting dashboard for application processing and licensing activities as well as copies of the submitted form "Application to Become a Licensed Producer Under the MMPR" and copies of the producer licences issued for Licensed Medical Marihuana Producers Bedrocan Canada Inc., Mettrum Ltd., Tilray, Tweed Inc. and Whistler Medical Marijuana Corp., or, the date of the aforementioned producers. (Jan. 1 to June 4, 2015) Disclosed in part 12
A-2015-00187 List of the names, salary ranges and classifications of all employees with a media relation or public information function, and information on the total pay and benefits costs for each of the last three completed fiscal years for media relations and communications. All disclosed 1
A-2015-00188 Copies of any consumer product complaints, incidents report and statistics in respect to incidents involving Polaris ATVs causing personal injuries. (July 7, 2003 to May 29, 2015) Disclosed in part 11
A-2015-00210 Number of Special Access Program (SAP) releases for the following drug for the years 2013 and 2014: Hydroxycobalamin. All disclosed 1
A-2015-00211 Copy of the briefing notes regarding the Quality Management System Enhancement Program pertaining to Food Inspection and its targeting of high-risk inspection activities (public risk). No records exist 0
A-2015-00215 List of request for proposals (RFPs) that included, in the title or description in 2014, the following key words: public consultation, public meeting, policy feedback, online consultation. No records exist 0
A-2015-00218 Documentation which indicates all appointments of term employees by the Public Health Agency of Canada in the National Capital Region under the term of the Public Service Employment Act during December 2014, January, February and March 2015. No records exist 0
A-2015-00222 Documentation which indicates all appointments of casual employees by this institution in the National Capital Region under the term of the Public Service Employment Act during December 2014, January, February and March 2015. All disclosed 3
A-2015-00223 Documentation which indicates all appointments of term employees by this institution in the National Capital Region under the term of the Public Service Employment Act during December 2014, January, February and March 2015. All disclosed 2
A-2015-00235 Copy of a letter sent by this institution to the Canadian Medical Cannabis Industry Association (CMCIA) in response to their request on the length of time required for the Royal Canadian Mountain Policy (RCMP) and this institution to perform a security check on additional Responsible Person in Charge (RPICs) and Alternate Responsible Person in Charge (ARPICs), and stating that it takes approximately 100 work days to process. (between June and October 2014) No records exist 0
A-2015-00243 Information regarding the number of clients registered with licensed producers under the Marihuana for Medical Purposes Regulations (MMPR) as at Jan. 31, 2015, Feb. 28, 2015, Mar. 31, 2015, Apr. 30, 2015 and May 31, 2015. All disclosed 1
A-2015-00244 Adverse Reaction Report (AER) for Ferrlecit (sodium ferric gluconate complex). Report number: 000634494. Disclosed in part 2
A-2015-00245 Adverse Reaction Report (AER) for Ferrlecit (sodium ferric gluconate complex). Report number: 000634495. Disclosed in part 1
A-2015-00246 Adverse Reaction Report (AER) for Lovenox (enoxaparin sodium). Report number: 000635972. Disclosed in part 1
A-2015-00261 List of all Twitter user names used by the department for official business as of June 23, 2015. All disclosed 1
A-2015-00268 Documents including statistics and other data on the number of licenses awarded and the number of licenses denied in order to verify whether the persons, companies or firms applied for a license to grow medical marijuana did or did not obtain accreditation following the screening checks carried out by the RCMP showing they have ties to one or more members of organized crime. (Apr. 1, 2014 to Jun. 24, 2015) Disclosed in part 56
A-2015-00282 Information related to the average length of time for a person to receive a single designated-person production licence under the previous Marihuana Medical Access Regulations once all relevant documents were in order, completed and submitted to this institution: data required for an individual breakdown of 2007, 2008, 2009, 2012 and 2013. No records exist 0
A-2015-00286 All documents in MECS for the following file: 15-000559-30. Subject: Invitation - National Public Policy Conference, Feb 28 to Mar 1, 2015 No records exist 0
A-2015-00288 All documents in MECS for the following file: 15-100998-303. Subject: MO Meeting with Alcohol Stakeholders on OECD 2014 Report on Alcohol Disclosed in part 3
A-2015-00291 All documents in MECS for the following file: 15-101372-969. Subject: Consultation on Drinking Water PH Guidelines and Consultation on Dechlorethane in Drinking Water All disclosed 4
A-2015-00292 All documents in MECS for the following file: 15-101878-676. Subject: Roundtable on Missing and Murdered Aboriginal Women.  Feb. 27, 2015 No records exist 0
A-2015-00293 All documents in MECS for the following file: 15-000896-779. Subject: Request for meeting on energy drinks for Feb 27/2015 Disclosed in part 2
A-2015-00299 All documents in MECS for the following file: 15-001064-817. Subject: Invitation to attend "Hike for Hospice" on May 3, 2015 Disclosed in part 1
A-2015-00302 All documents in MECS for the following file: 15-102841-476. Subject: Minister's office request on First Nations Water and Wastewater Action Plan No records exist 0